Scarica l'app Stockscreener
23.20
3.97%
-0.96
Dopo l'orario di chiusura:
23.75
0.55
+2.37%
Precedente Chiudi:
$24.16
Aprire:
$24.6
Volume 24 ore:
1.55M
Relative Volume:
1.18
Capitalizzazione di mercato:
$2.77B
Reddito:
$22.57M
Utile/perdita netta:
$-212.73M
Rapporto P/E:
-12.86
EPS:
-1.8045
Flusso di cassa netto:
$-142.19M
1 W Prestazione:
+2.75%
1M Prestazione:
-9.34%
6M Prestazione:
-29.68%
1 anno Prestazione:
-24.43%
Intervallo 1D:
$22.67
$24.75
Intervallo di 1 settimana:
$22.25
$25.12
Portata 52W:
$21.02
$42.20
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Nome
Newamsterdam Pharma Company Nv
Settore
Industria
Telefono
35 206 2971
Indirizzo
GOOIMEER 2-35, NARRDEN
Compare NAMS vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
23.20 | 2.70B | 22.57M | -212.73M | -142.19M | -1.8045 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-18 | Iniziato | Truist | Buy |
| 2025-10-20 | Ripresa | H.C. Wainwright | Buy |
| 2025-08-25 | Iniziato | Wells Fargo | Overweight |
| 2025-07-17 | Iniziato | Goldman | Neutral |
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2025-06-10 | Iniziato | Stifel | Buy |
| 2025-06-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-15 | Iniziato | TD Cowen | Buy |
| 2024-03-14 | Iniziato | Scotiabank | Sector Outperform |
| 2024-01-18 | Iniziato | Guggenheim | Buy |
| 2024-01-16 | Iniziato | Piper Sandler | Overweight |
| 2023-10-30 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Newamsterdam Pharma Company Nv Borsa (NAMS) Ultime notizie
NewAmsterdam Pharma: Can Obicetrapib's Data In Diabetes And Metabolic Syndrome Bring Back The Mojo? - RTTNews
NewAmsterdam Pharma Company N.V. Actuals & Estimates (HAN:KH6) - TradingView
NewAmsterdam Pharma Company N.V. (NAMS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Enterprise value of NewAmsterdam Pharma Company N.V. – HAN:KH6 - TradingView
ETFs Investing in NewAmsterdam Pharma Company N.V. Stocks - TradingView
NewAmsterdam Pharma Doses First Participant in Phase 2b Trial for Preclinical Alzheimer's Disease - marketscreener.com
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease - The Manila Times
NewAmsterdam Pharma Company N.V. Doses First Participant In Phase 2b SPINOZA Trial Evaluating Obicetrapib In Preclinical Alzheimer?s Disease - marketscreener.com
Price-Driven Insight from (NAMSW) for Rule-Based Strategy - Stock Traders Daily
Menarini and NewAmsterdam Receive EU Approval for New Drugs - Intellectia AI
NewAmsterdam Pharma (NAMS) Wins EU Approvals. Can Cholesterol Pills Drive Royalties? - insidermonkey.com
NewAmsterdam, Menarini Secure EU Approval for Obicetrapib-Based Ubeslo and Evlarco - BioPharma APAC
Five Frazier funds detail their NewAmsterdam (NASDAQ: NAMS) positions - Stock Titan
(NAMS) Volatility Zones as Tactical Triggers - Stock Traders Daily
NewAmsterdam Pharma wins EU approval for obicetrapib as Ubeslo and Evlarco - TradingView
EU clears NewAmsterdam Pharma (NAMS) cholesterol drug, unlocking milestone payouts with its partner - Stock Titan
Menarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) | Corporate - EQS News
Stifel reiterates NewAmsterdam Pharma stock rating on EU approval By Investing.com - Investing.com Canada
Stifel reiterates NewAmsterdam Pharma stock rating on EU approval - Investing.com
Menarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) - PR Newswire
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) - marketscreener.com
Two new cholesterol drugs get their first global approval in Europe - Stock Titan
NAMS Q2 2026 Earnings: Wider-Than-Expected Loss as Clinical-Stage Spending ContinuesProfit Recovery Report - dars.gov.et
NewAmsterdam Pharma (NAMS) Stock Looks Above Fair Value After Its 139% Run - Yahoo Finance
(NAMSW) Movement as an Input in Quant Signal Sets - Stock Traders Daily
NewAmsterdam Pharma stock rises as CEO buys $226.5K in stock By Investing.com - za.investing.com
NewAmsterdam Pharma stock rises as CEO buys $226.5K in stock - Investing.com
NewAmsterdam Pharma (NAMS) CEO adds to stake with fresh share purchase - Stock Titan
Precision Trading with Newamsterdam Pharma Company N.v. (NAMS) Risk Zones - Stock Traders Daily
NewAmsterdam Pharma at Cantor conference: obicetrapib nears key test - Investing.com
NewAmsterdam Pharma at Cantor conference: obicetrapib nears key test By Investing.com - Investing.com UK
Newamsterdam Pharma stock hits 52-week low at 23.02 USD By Investing.com - Investing.com India
NewAmsterdam Pharma at Wells Fargo conference: obicetrapib push By Investing.com - Investing.com UK
NewAmsterdam Pharma (NAMS) director sells shares to cover tax bill - Stock Titan
Newamsterdam Pharma stock hits 52-week low at 23.02 USD - investing.com
NewAmsterdam Pharma: Potential Coupled With Uncertainty (NASDAQ:NAMS) - Seeking Alpha
Stifel reiterates Buy on NewAmsterdam Pharma stock after trial failure By Investing.com - Investing.com Nigeria
Stifel reiterates Buy on NewAmsterdam Pharma stock after trial failure - Investing.com
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Price to earnings forward of NewAmsterdam Pharma Company N.V. – BOATS:NAMSW - TradingView
Why (NAMSW) Price Action Is Critical for Tactical Trading - Stock Traders Daily
NewAmsterdam Pharma Company N.V. - Reuters
(KH6.F) | Stock Price & Latest News - reuters.com
NewAmsterdam Pharma VP Robert Gunning Granted 3,200 RSUs and 14,000 Stock Options - Kalkine Media
NewAmsterdam Pharma (NAMS) awards 14,000 options and 3,200 RSUs to controller - Stock Titan
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
NAMS Q2 2026 Earnings: Quarterly Net Loss Widens Slightly on R&D InvestmentPre-Earnings Setup - vinanet.vn
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September - The Manila Times
NAMSW Warrant Holds Flat at $16.51 as Consolidation Persists Below $17.34 ResistanceVolatility Term Structure - dars.gov.et
NewAmsterdam Pharma Company NV (NAMS) Valuation: PE, PB & Fair Value Analysis - TradingKey
NewAmsterdam Pharma Company N.V. Warrant (NASDAQ: NAMSW) Stock Price, News & Analysis - kalkine.ca
Newamsterdam Pharma Company Nv Azioni (NAMS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Newamsterdam Pharma Company Nv Azioni (NAMS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Smither John W | Director |
Sep 04 '26 |
Sale |
25.32 |
1,600 |
40,512 |
8,760 |
| Kastelein Johannes Jacob Piete | Chief Scientific Officer |
Aug 24 '26 |
Sale |
26.91 |
125,000 |
3,363,750 |
69,302 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):